Subtype
Prostate Neoplasm
CI-CAN-00003778Explore in graph →
Non-malignant1,453 active trials24 approved drugs58 evidence items
Loading cancer entity…
Loading cancer entity…
Subtype
CI-CAN-00003778Explore in graph →
Clinical trials
6,544 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT02768363 | Randomized Controlled Trial of CAN-2409 Immunotherapy During Active Surveillance for Prostate Cancer (ULYSSES) | active not recruiting | Phase 2 | 187 | Candel Therapeutics, Inc.INDUSTRY | 2 | Jul 30, 2025 | clinicaltrials |
| NCT04181203 | Combined Apalutamide, Radiotherapy, and LHRH Agonist in Prostate Cancer Patients After Prostatectomy(CARLHA-2) | active not recruiting | Phase 3 | 490 | UNICANCEROTHER | 1 | Jul 30, 2025 |
| clinicaltrials |
| NCT05269550 | PSMA MRI Guided Prostate SBRT (ARGOS)/Comprehensive, Longitudinal Evaluation of Imaging Biomarkers Post Radiotherapy (CLIMBER)(ARGOS/CLIMBER) | active not recruiting | N/A | 50 | London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph'sOTHER | 1 | Jul 28, 2025 | clinicaltrials |
| NCT04404894 | Long-Term Prospective Registry in Prostate Cancer Patients From Diverse Urology Practice Settings Following Prolaris® Testing | active not recruiting | — | 500 | Myriad Genetic Laboratories, Inc.INDUSTRY | 1 | Jul 14, 2025 | clinicaltrials |
| NCT07048613 | Comparative Study of MRI and TU in Identifying Clinically Significant Prostate Cancer Among Ethnic Groups | active not recruiting | — | 120 | Superior UniversityOTHER | 1 | Jul 2, 2025 | clinicaltrials |
| NCT05768776 | Outpatient Holmium LASER Enucleation of the Prostate: Benefit of MOSES(TM) 2.0 Technology(MOSES) | active not recruiting | — | 200 | University Hospital, BordeauxOTHER | 1 | Jun 25, 2025 | clinicaltrials |
| NCT04105920 | Evaluation of the Interest of Hyaluronic Acid in the Preservation of Sexual Function During Prostate Curietherapies(HYALEREC) | active not recruiting | N/A | 162 | Hospices Civils de LyonOTHER | 1 | Jun 24, 2025 | clinicaltrials |
| NCT01342367 | Feasibility of Hormones and Radiation for Intermediate or High Risk Prostate Cancer | active not recruiting | N/A | 74 | University of ChicagoOTHER | 1 | Jun 10, 2025 | clinicaltrials |
| NCT02804815 | Add-Aspirin: A Trial Assessing the Effects of Aspirin on Disease Recurrence and Survival After Primary Therapy in Common Non Metastatic Solid Tumours | active not recruiting | Phase 3 | 11,000 | University College, LondonOTHER | 2 | Jun 10, 2025 | clinicaltrials |
| NCT01550237 | Curative Image Guided Radiotherapy for Prostate Cancer(RIC) | active not recruiting | N/A | 260 | St. Olavs HospitalOTHER | 1 | Jun 5, 2025 | clinicaltrials |
| NCT03564275 | Proton Boost in Prostate Cancer | active not recruiting | N/A | 10 | University of CincinnatiOTHER | 1 | May 31, 2025 | clinicaltrials |
| NCT03392181 | PET/MRI for the Staging of Newly Diagnosed Prostate Cancer | active not recruiting | Early Phase 1 | 48 | Northwestern UniversityOTHER | 1 | May 23, 2025 | clinicaltrials |
| NCT06985004 | Predicting Operational Difficulties and Outcomes of RARP Based on Preoperative Assessment - Introducing the PIODO Questionnaire | active not recruiting | — | 288 | Pomeranian Medical University SzczecinOTHER | 1 | May 22, 2025 | clinicaltrials |
| NCT06383052 | A Phase 1/2 Study of 177Lu-NYM032 Injection in mCRPC | active not recruiting | Phase 1 / Phase 2 | 30 | Norroy Bioscience Co., LTDINDUSTRY | 1 | May 21, 2025 | clinicaltrials |
| NCT04848909 | Stereotactic Body Radiotherapy (SBRT) Post Prostatectomy(PLUTO-MPC) | active not recruiting | N/A | 30 | Sunnybrook Health Sciences CentreOTHER | 1 | May 15, 2025 | clinicaltrials |
| NCT03874884 | 177Lu-PSMA-617 Therapy and Olaparib in Patients With Metastatic Castration Resistant Prostate Cancer(LuPARP) | active not recruiting | Phase 1 | 70 | Peter MacCallum Cancer Centre, AustraliaOTHER | 1 | May 14, 2025 | clinicaltrials |
| NCT04484701 | [68Ga]Ga-PSMA-11 PET/CT in the Assessment of High Risk and Recurrent Prostate Cancer | active not recruiting | — | 1,574 | British Columbia Cancer AgencyOTHER | 1 | May 9, 2025 | clinicaltrials |
| NCT03703778 | Real-life Evaluation of the Effect of ADT in Prostate Cancer Patients in Asia (READT Asia Study)(READT) | active not recruiting | — | 300 | Chinese University of Hong KongOTHER | 1 | May 6, 2025 | clinicaltrials |
| NCT05179824 | Tempus Priority Study: A Pan-tumor Observational Study | active not recruiting | — | 1,000 | Tempus AIINDUSTRY | 1 | May 6, 2025 | clinicaltrials |
| NCT04253262 | A Study of Copanlisib Combined With Rucaparib in Patients With Metastatic Castration-resistant Prostate Cancer | active not recruiting | Phase 1 / Phase 2 | 13 | Brown UniversityOTHER | 1 | May 4, 2025 | clinicaltrials |
| NCT03998657 | Continued Access of Focal MR-Guided Focused Ultrasound for Localized Intermediate Risk Prostate Lesions | active not recruiting | N/A | 14 | InSightecINDUSTRY | 1 | May 1, 2025 | clinicaltrials |
| NCT06950307 | Hypofractionation for Prostate Cancer in Africa: A Feasibility Study(HypoAfrica) | active not recruiting | — | 182 | Muhimbili University of Health and Allied SciencesOTHER | 3 | Apr 30, 2025 | clinicaltrials |
| NCT03689699 | Nivolumab and BMS-986253 for Hormone-Sensitive Prostate Cancer (MAGIC-8) | active not recruiting | Phase 1 / Phase 2 | 59 | Mark SteinOTHER | 1 | Apr 29, 2025 | clinicaltrials |
| NCT03857477 | The BARCODE 1 Study (Full Study): The Use of Genetic Profiling to Guide Prostate Cancer Targeted Screening.(BARCODE1) | active not recruiting | — | 4,700 | Institute of Cancer Research, United KingdomOTHER | 1 | Apr 29, 2025 | clinicaltrials |
| NCT06935487 | European Multicenter Validation of PCaVision: A Head-to-Head Diagnostic Accuracy Study Comparing Multiparametric Transrectal Ultrasound to MRI for Clinically Significant Prostate Cancer Detection(PCaVISTA) | active not recruiting | N/A | 806 | Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)OTHER | 6 | Apr 20, 2025 | clinicaltrials |
| NCT06458855 | Nerve Grafting Technique to Restore Erectile Function Post Radical Prostatectomy(PRP-NR) | active not recruiting | N/A | 10 | Sir Mortimer B. Davis - Jewish General HospitalOTHER | 1 | Apr 18, 2025 | clinicaltrials |
| NCT06929884 | Effectiveness, Safety, and Economic Evaluation of Goserelin Microspheres for Injection and Goserelin Sustained-Release Implants in Prostate Cancer Patients: A Real-World Study | active not recruiting | — | 400 | Qianfoshan HospitalOTHER | 1 | Apr 16, 2025 | clinicaltrials |
| NCT04706962 | TH1902 in Patients With Advanced Solid Tumors | active not recruiting | Phase 1 | 70 | TheratechnologiesINDUSTRY | 2 | Apr 15, 2025 | clinicaltrials |
| NCT01653093 | 3-Tesla MRI in Finding Tumors in Patients With Known or Suspected Prostate Cancer | active not recruiting | N/A | 280 | University of CincinnatiOTHER | 1 | Apr 11, 2025 | clinicaltrials |
| NCT05340374 | Cabazitaxel in Combination With 177Lu-PSMA-617 in Metastatic Castration-resistant Prostate Cancer(LuCAB) | active not recruiting | Phase 1 / Phase 2 | 35 | Peter MacCallum Cancer Centre, AustraliaOTHER | 1 | Apr 6, 2025 | clinicaltrials |
| NCT05608746 | Prehabilitation in Prostate Cancer Patients, TelePrehabTrial | active not recruiting | N/A | 40 | University of AarhusOTHER | 1 | Apr 6, 2025 | clinicaltrials |
| NCT04302454 | Androgen Deprivation Therapy for Oligo-recurrent Prostate Cancer in Addition to radioTherapy(ADOPT) | active not recruiting | Phase 3 | 280 | University Medical Center GroningenOTHER | 1 | Apr 4, 2025 | clinicaltrials |
| NCT06850116 | Analysis of Immediate Urinary Continence Predictors After RS-RARP | active not recruiting | — | 400 | First Affiliated Hospital of Fujian Medical UniversityOTHER | 1 | Apr 4, 2025 | clinicaltrials |
| NCT04802876 | Efficacy of Tislelizumab and Spartalizumab Across Multiple Cancer-types in Patients with PD1-high MRNA Expressing Tumors(ACROPOLI) | active not recruiting | Phase 2 | 184 | SOLTI Breast Cancer Research GroupOTHER | 1 | Mar 21, 2025 | clinicaltrials |
| NCT03525288 | PSMA-PET Guided Radiotherapy(PSMA-PETgRT) | active not recruiting | Phase 2 / Phase 3 | 130 | Centre hospitalier de l'Université de Montréal (CHUM)OTHER | 1 | Mar 13, 2025 | clinicaltrials |
| NCT04557501 | PSMA PET/CT Guided Intensification of Therapy in Patients at Risk of Advanced Prostate Cancer(PATRON) | active not recruiting | Phase 3 | 800 | Centre hospitalier de l'Université de Montréal (CHUM)OTHER | 1 | Mar 13, 2025 | clinicaltrials |
| NCT05523856 | New Treatment Modalities for Localized Prostate Cancer(TTOPROST/OBS) | active not recruiting | — | 480 | Fundacion IMIMOTHER | 0 | Mar 12, 2025 | clinicaltrials |
| NCT01492751 | Effectiveness of Localized Prostate Cancer Treatments(E-PROSTCaT) | active not recruiting | — | 500 | Fundacion IMIMOTHER | 1 | Feb 28, 2025 | clinicaltrials |
| NCT03822494 | CyberKnife Dose Escalation Prostate Cancer Trial(CK-DESPOT) | active not recruiting | N/A | 100 | Crozer-Keystone Health SystemOTHER | 1 | Feb 21, 2025 | clinicaltrials |
| NCT05917860 | Neoadjuvant ADT with TULSA in the Treatment of Intermediate Risk Prostate Cancer(NeoADT-TULSA) | active not recruiting | Phase 1 | 15 | Turku University HospitalOTHER_GOV | 1 | Feb 17, 2025 | clinicaltrials |
| NCT02302105 | Randomized Trial of Prostate Only or Pelvic RT in High Risk Prostate Cancer(POP-RT) | active not recruiting | N/A | 224 | Tata Memorial CentreOTHER | 1 | Feb 13, 2025 | clinicaltrials |
| NCT06820502 | OUTCOMES of SIMULTANEOUS TRANSURETHRAL PROSTATE and BLADDER TUMOR RESECTION VERSUS TRANSURETHRAL BLADDER TUMOR RESECTION in BLADDER TUMOR with BLADDER PROSTATE HYPERPLASIA | active not recruiting | N/A | 60 | Allama Iqbal Medical CollegeOTHER | 1 | Feb 11, 2025 | clinicaltrials |
| NCT02176902 | Low-Fat Diet and Fish Oil in Men on Active Surveillance for Prostate Cancer | active not recruiting | N/A | 107 | Jonsson Comprehensive Cancer CenterOTHER | 1 | Feb 10, 2025 | clinicaltrials |
| NCT03763253 | Additional Treatments to the Local Tumour for Metastatic Prostate Cancer: Assessment of Novel Treatment Algorithms(IP2-ATLANTA) | active not recruiting | Phase 2 | 433 | Imperial College LondonOTHER | 1 | Feb 7, 2025 | clinicaltrials |
| NCT05032040 | A Study of XmAb20717 (Vudalimab)in Patients With Selected Advanced Gynecologic and Genitourinary Malignancies | active not recruiting | Phase 2 | 170 | Xencor, Inc.INDUSTRY | 1 | Feb 7, 2025 | clinicaltrials |
| NCT05383079 | Combination of Radium-223 and Lutetium-177 PSMA-I&T in Men with Metastatic Castration-Resistant Prostate Cancer(AlphaBet) | active not recruiting | Phase 1 / Phase 2 | 36 | Peter MacCallum Cancer Centre, AustraliaOTHER | 1 | Feb 7, 2025 | clinicaltrials |
| NCT02446405 | Enzalutamide in First Line Androgen Deprivation Therapy for Metastatic Prostate Cancer(ENZAMET) | active not recruiting | Phase 3 | 1,125 | University of SydneyOTHER | 6 | Feb 6, 2025 | clinicaltrials |
| NCT00223145 | Study on the Role of Hormonal Treatment for Two Dosage Levels of Prostate Radiation Therapy Versus Prostate Radiation Therapy Alone(PCS III) | active not recruiting | Phase 3 | 600 | Abdenour NabidOTHER | 1 | Jan 27, 2025 | clinicaltrials |
| NCT00223171 | Duration of Androgen Blockade Combined With Pelvic Irradiation in Prostate Cancers(PCS IV) | active not recruiting | Phase 3 | 630 | Université de SherbrookeOTHER | 1 | Jan 27, 2025 | clinicaltrials |
| NCT05348577 | Study of Capivasertib + Docetaxel vs Placebo + Docetaxel as Treatment for Metastatic Castration Resistant Prostate Cancer (mCRPC)(CAPItello280) | active not recruiting | Phase 3 | 1,035 | AstraZenecaINDUSTRY | 22 | Jan 27, 2025 | clinicaltrials |
Data updated 22 days agoSource updated Jul 30, 2025source: clinicaltrials